Allergan Settles Botox Off-Label Claims For $600M
Allergan Inc. reached a $600 million settlement with the U.S. Department of Justice on Wednesday to resolve criminal and civil claims stemming from the company's marketing of off-label uses for its...To view the full article, register now.
Already a subscriber? Click here to view full article